Krishna S Vishnupad

USPTO Granted Patents = 9 (Patent Applications = 1)

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 3.3

ph-index = 9

Forward Citations = 664(Granted Patents)

Company Filing History:

5 out of 12

Eurand Pharmaceuticals, Ltd.

patents

2 out of 11

Aptalis Pharmatech, Inc.

Adare Pharmaceuticals, Inc.

patents

Years Active: 2002-2016

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9358214 - Timed, sustained release systems for propranolol (2016-06-07),

2. 9040086 - Timed, sustained release systems for propranolol (2015-05-26),

3. 8367111 - Extended release dosage forms of propranolol hydrochloride (2013-02-05),

4. 7048945 - Timed pulsatile drug delivery systems (2006-05-23),

5. 6663888 - Pulsatile release histamine H2 antagonist dosage form (2003-12-16),

6. 6627223 - Timed pulsatile drug delivery systems (2003-09-30),

7. 6500454 - Timed, sustained release systems for propranolol (2002-12-31),

8. 6451345 - Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration (2002-09-17),

9. 6344215 - Methylphenidate modified release formulations (2002-02-05),

Title: Biography of Krishna S Vishnupad

Introduction

Krishna S Vishnupad is an accomplished inventor based in Dayton, OH (US). He holds a total of 9 patents, showcasing his significant contributions to the field of pharmaceutical innovations. His work primarily focuses on drug delivery systems that align with physiological needs.

Latest Patents

One of his latest patents involves timed, sustained release systems for propranolol. This invention is a unit dosage form, such as a capsule, designed to deliver drugs into the body in a circadian release fashion. It comprises one or more populations of propranolol-containing particles, such as beads or pellets. Each bead population exhibits a pre-designed rapid or sustained release profile, with or without a predetermined lag time of 3 to 5 hours. This cardiovascular drug delivery system aims to provide a plasma concentration-time profile that varies according to physiological needs throughout the day, mimicking the circadian rhythm and addressing the severity of cardiovascular diseases.

Career Highlights

Throughout his career, Krishna has worked with notable companies in the pharmaceutical industry, including Eurand Pharmaceuticals, Ltd. and Aptalis Pharmatech, Inc. His experience in these organizations has contributed to his expertise in drug formulation and delivery systems.

Collaborations

Krishna has collaborated with several professionals in his field, including Gopi M Venkatesh and Phillip J Percel. These collaborations have further

This text is generated by artificial intelligence and may not be accurate.